Functional Activity and Binding Specificity of small Ankyrin Repeat Proteins called Ankyrons against SARS-CoV-2 variants.
Yun-Jong ParkiD, Wojciech JankowskiiD, Nicholas C. Hurst, Jeremy W. FryiD, Nikolai F. Schwabe, Linda C. C. Tan, Zuben E. SaunaiD
Abstract
Effective management of COVID-19 requires clinical tools to treat the disease in addition to preventive vaccines. Several recombinant mAbs and their cocktails have been developed to treat COVID-19 but these have limitations. Here, we evaluate small ankyrin repeat proteins called Ankyrons that were generated to bind with high affinity to the SARS-CoV-2 virus. Ankyrons are ankyrin repeat proteins comprised of repetitions a structural module. Each module consists of a {beta}-turn followed by two antiparallel -helices. The Ankyrons are directly selected in vitro from a highly diverse library of around a trillion clones in ribosome display and like antibodies can bind with high affinity to almost any target. We assessed Ankyrons that were generated against the wild-type SARS-CoV-2 and the Delta and Omicron variants in a binding assay. We determined that all Ankyrons were specific in that they did not bind to MERS, a related coronavirus. While all Ankyrons bound with high affinity to the variant they were generated against, some also showed cross-reactivity to all three SARS-CoV-2 variants. Binding assays are useful for screening analytes but do not provide information about clinical effectiveness. Therefore, we used a pseudovirus-based neutralization assay to show that five of the Ankyrons evaluated neutralized all three strains of SARS-CoV-2. We have provided a workflow for the evaluation of novel Ankyrons against a viral target. This suggests that Ankyrons could be useful for rapidly developing new research tools for studying other emerging infectious diseases rapidly with the optional further potential for developing Ankyrons into diagnostic and even therapeutic applications. Author SummaryYun-Jong Park: Investigation, Methodology, Format Analysis, Writing - original draft. Wojciech Jankowski: Methodology, Format Analysis, and Review. Nicholas C Hurst, Jeremy W Fry, Nikolai F Schwabe and Linda C C Tan: Resources, Review & Editing. Zuben E Sauna: Conceptualization, Supervision, Writing - original draft and Final editing.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 1.34
- Field percentile
- top 24%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cross-Neutralizing Monoclonal Antibodies with Broad Activity Against Human and Bat-Derived SARS-Related Coronaviruses
Martin Mayora Neto, Kelly da Costa, … Nigel James Temperton·bioRxiv·Aug 14, 2025
- A cell-based, spike protein binding assay highlights differences in antibody neutralising capacity for SARS-CoV-2 variants
N. Harrison, L. Richardson, … O. S. Qureshi·bioRxiv·Jun 24, 2022
- High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
Joshua J. Sims, Sharon Lian, … James M. Wilson·PLoS ONEPeer-reviewed·Aug 25, 2022
- Broadly effective ACE2 decoy proteins protect mice from lethal SARS-CoV-2 infection
M. Lu, W. Yao, … G. Zhong·Microbiology SpectrumPeer-reviewed·Aug 17, 2023
- Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants
- Potent human neutralizing antibodies elicited by SARS-CoV-2 infection